Trinity Biotech
TRIBTrinity Biotech is a publicly traded diagnostics company focused on transforming healthcare through innovative testing solutions. The company has achieved significant milestones, including regaining compliance with Nasdaq listing requirements and securing regulatory approvals for offshored manufacturing of its flagship HIV test. With a diversified portfolio spanning infectious disease, autoimmune, hemoglobin, and clinical chemistry testing, Trinity Biotech aims to improve patient outcomes globally while executing a strategic transformation to enhance financial performance.
TRIB · Stock Price
Historical price data
AI Company Overview
Trinity Biotech is a publicly traded diagnostics company focused on transforming healthcare through innovative testing solutions. The company has achieved significant milestones, including regaining compliance with Nasdaq listing requirements and securing regulatory approvals for offshored manufacturing of its flagship HIV test. With a diversified portfolio spanning infectious disease, autoimmune, hemoglobin, and clinical chemistry testing, Trinity Biotech aims to improve patient outcomes globally while executing a strategic transformation to enhance financial performance.
Technology Platform
Multiple diagnostic technology platforms including immunoassay (lateral flow), high-performance liquid chromatography (HPLC) for hemoglobin analysis, clinical chemistry analyzers, and specialized transport media for specimen preservation.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Trinity Biotech competes with major diagnostic companies including Abbott, Bio-Rad, Siemens Healthineers, and Thermo Fisher across various segments. Differentiation comes from specialized expertise in hemoglobin testing (IFCC Gold Classification), established HIV rapid tests, and reference laboratory services for autoimmune diagnostics through its Immco division.